You are here

New App for Dementia Assessment

Software to be available by June 2013 (Mar. 12)

Clinicians in Sydney, Australia, and Plymouth, U.K., have taken the paper-based Addenbrooke’s Cognitive Examination (ACE) — a commonly used screening tool for dementia — and have translated it into app form for more accurate assessment and wider use by clinical teams.

The app is called ACEmobile, and it uses the latest version of ACE (ACE-III). It will be launched at the Healthcare Innovation Expo 2013 in London on March 13. The developers intend ACEmobile to be made available free of charge to dementia clinicians around the world via iTunes and Google Play.

ACEmobile automatically scores and produces automated reports, and supports the routine collection of clinical data, which can help individual clinical teams to audit their own dementia assessment practices. The app may also serve as a research tool.

“ACE-III is a great assessment tool, but as with many such tools which are paper-based, it has been open to human error and miscalculation,” said Dr. Rupert Noad. “By producing the ACEmobile app, we have reduced the risk of such error and miscalculation and have created a tool which can be used by the wider dementia care team.”

He added: “Early diagnosis is important because it allows us, along with the patient and those close to them, to prepare a plan of care which can mean greater independence and which can introduce therapies and strategies that may slow down the development of the disease.”

The ACEmobile app is expected to be available for download from iTunes and Google Play by June 2013.

Source: Plymouth University; March 12, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation